Literature DB >> 7419271

Effects of prazosin on autonomic control of circulation in essential hypertension.

G Mancia, A Ferrari, L Gregorini, M C Ferrari, C Bianchini, L Terzoli, G Leonetti, A Zanchettie.   

Abstract

Prazosin, an antihypertensive agent that reduces blood pressure (BP) mainly through a blockade of alpha-adrenergic receptors, may, in theory, affect sympathetic control of circulation to an extent that impairs circulatory hemeostasis. This possibility was studied in subjects with essential hypertension by examining the cardiovascular effects of several stimuli that induce a powerful and diversified activation of the sympathetic noradrenergic activity (dynamic and isometric exercise, cold exposure) and of stimuli that exert a powerful inhibitory influence upon the sympathetic nervous system (carotid baroreceptor reflex). Before and after 15 days of continuous administration of prazosin (2-5 mg), 3 times a day, measurements were made of BP (intraarterial catheter), heart rate, cardiac output (thermodilution), and peripheral resistance. Prazosin reduced mean arterial pressure (10%) and peripheral resistance (9%) at rest, and it did not affect heart rate and cardiac output. Neurally mediated changes in arterial pressure, cardiac output, and peripheral resistance during dynamic or isometric exercise and cold exposure were unaffected by the drug; also unaffected were the cardiovascular responses to increase and decrease in carotid baroreceptor activity obtained by varying carotid transmural pressure through a variable neck pressure chamber device. Thus, the hypotensive and vasodilating effect of prazosin in essential hypertension is not accompanied by an impaired response to neural excitation influences upon the cardiovascular system. Also, the inhibitory influences originating from the carotid baroreflex are unchanged. These data indicate that circulatory homeostasis is largely preserved during administration of prazosin at clinically effective doses.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 7419271     DOI: 10.1161/01.hyp.2.5.700

Source DB:  PubMed          Journal:  Hypertension        ISSN: 0194-911X            Impact factor:   10.190


  9 in total

1.  Dose-titration study of alfuzosin, a new alpha 1-adrenoceptor blocker, in essential hypertension.

Authors:  S Leto di Priolo; P Priore; G Cocco; C Sfrisi; J L Cazor
Journal:  Eur J Clin Pharmacol       Date:  1988       Impact factor: 2.953

2.  Effect of indapamide on the baroreceptor reflex in essential hypertension.

Authors:  R Carretta; B Fabris; L Tonutti; G Bellini; G Battilana; A Bianchetti; L Campanacci
Journal:  Eur J Clin Pharmacol       Date:  1983       Impact factor: 2.953

3.  The effect of prazosin on skin microcirculation as assessed by laser Doppler flowmetry.

Authors:  F Khan; A D Struthers; V A Spence
Journal:  Br J Clin Pharmacol       Date:  1988-09       Impact factor: 4.335

4.  Ketanserin and the arterial baroreceptor reflex in normotensive subjects.

Authors:  A Berdeaux; A Edouard; K Samii; J F Giudicelli
Journal:  Eur J Clin Pharmacol       Date:  1987       Impact factor: 2.953

5.  Gender-modulated endogenous baseline neuropeptide Y Y1-receptor activation in the hindlimb of Sprague-Dawley rats.

Authors:  Dwayne N Jackson; Kevin J Milne; Earl G Noble; J Kevin Shoemaker
Journal:  J Physiol       Date:  2004-10-28       Impact factor: 5.182

6.  Prazosin depression of baroreflex function in hypertensive man.

Authors:  E H Sasso; D T O'Connor
Journal:  Eur J Clin Pharmacol       Date:  1982       Impact factor: 2.953

7.  Within patient comparison of prazosin and UK-33,274. A new alpha-adrenoceptor-antagonist.

Authors:  P W de Leeuw; J J Ligthart; A J Smout; W H Birkenhäger
Journal:  Eur J Clin Pharmacol       Date:  1982       Impact factor: 2.953

8.  Neural control of circulation before and after intravenous urapidil in essential hypertension.

Authors:  G Grassi; G Parati; G Pomidossi; G Giannattasio; R Casadei; A Groppelli; A Zanchetti; G Mancia
Journal:  Drugs       Date:  1988       Impact factor: 9.546

Review 9.  Prazosin update. A review of its pharmacological properties and therapeutic use in hypertension and congestive heart failure.

Authors:  W F Stanaszek; D Kellerman; R N Brogden; J A Romankiewicz
Journal:  Drugs       Date:  1983-04       Impact factor: 9.546

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.